Table 1.
Measures of prostate cancer quality
| Timing relative to primary treatment | Measure | Endorsing Organization | Hypersensitive to health system integration |
|---|---|---|---|
| Pre-treatment | |||
| Received pretreatment counseling by a urologist and radiation oncologist | RAND | ✔ | |
| Avoided imaging in patients with low risk prostate cancer | PCPI, NQF | ||
| Obtained imaging in patients with high risk prostate cancer | PCPI, NQF | ||
| Peri-treatment | |||
| Treated by a high volume provider | |||
| Avoided treatment when life expectancy <10 years | AUA | ✔ | |
| Received ADT with radiation for high risk prostate cancer | PCPI, NQF | ||
| Received adjuvant radiation after surgery for high risk prostate cancer | RAND | ||
| Post-treatment | |||
| At least 2 follow-up visits with treating provider after treatment | RAND | ✔ | |
| Experienced GI toxicity related to treatment | RAND | ||
| Experienced GU toxicity related to treatment | RAND | ||
| Received chemotherapy in the last 14 days of life | NQF | ✔ | |
| Avoidance of multiple hospital admissions in last 30 days of life (>1) | NQF | ✔ | |
AUA: American Urological Association, PCPI Physician Consortium for Performance Improvement, NQF: National Quality Forum